Company intelligence / Profile preview
PBG BioPharma
- Ownership
- Private
- Employees
- ~24
- Development stage
- Other
Overview
PBG BioPharma has a proven track record with successful commercialized natural health products such as COLD-FX®, ongoing clinical studies in cannabis-based medicines for chronic pain and mental health disorders in partnership with Canadian universities. They are developing new therapies using plant-derived compounds including cannabinoids and psychedelics; some programs are at the preclinical or early clinical stage while their nutraceuticals are already on the market.
- Therapeutic areas
- NeurologyPsychiatryInfectious DiseasesOncologyImmunology
- Modalities
- Small moleculePlant-derived compoundCannabinoid-based productPsychedelic compound (e.g., psilocybin)Nutraceutical
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on PBG BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PBG BioPharma.